A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT06981988
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Relapsed/Refractory Indolent NHL

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The study is being conducted to evaluate the reasonable dosage, efficacy and safety of Linperlisib in combination with rituximab in subjects with relapsed/refractory (R/R) indolent non-hodgkin lymphoma(NHL) in adults.

Key Dates

Start date
Jun 30, 2025
Status verified
May 2025
Primary completion
Aug 31, 2025
Completion
Feb 28, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Linperlisib + Rituximab

Primary Outcome Measure

MTD （Maximum tolerated dose）of Linperlisib（Stage 1） [ Time Frame: Subjects are evaluated for DLTs during the first 28-day cycle ]

Central Contacts